Related Experiment Video

Updated: May 13, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation

Carolyn Bentley1, Stefanie S Jurinka, Noelyn M Kljavin

  • 1Department of Discovery Oncology, Department of Bioinformatics, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

The Biochemical Journal
|March 19, 2013
PubMed

Insights

Wild-type (WT) Ras genes, HRas, NRas, and KRas, have unique roles in mutant KRas-driven cancers. Disrupting WT HRas or NRas impacts signaling pathways and cell behavior, but not tumor growth in xenografts.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Mutant Ras proteins (KRas, NRas, HRas) are key drivers of human cancers.
  • The function of wild-type (WT) Ras alleles and isoforms in cancer remains less understood.
  • Endometrial cancer cell lines with mutant KRas often retain WT HRas and NRas.

Purpose of the Study:

  • To investigate the role of WT HRas and NRas in a mutant KRas-driven cancer model.
  • To determine the impact of disrupting WT Ras isoforms on cancer cell signaling and behavior.
  • To elucidate the unique contributions of WT Ras alleles in the context of oncogenic KRas.

Main Methods:

  • Utilized zinc-finger nucleases to disrupt both alleles of HRas and NRas in the Hec1A endometrial cancer cell line.
  • Analyzed growth-factor-dependent signaling pathways, including ERK and Akt.
  • Assessed cell proliferation, apoptosis, anchorage-independent growth, and xenograft tumor growth.

Main Results:

  • Disruption of WT HRas or NRas impaired ERK pathway signaling.
  • HRas disruption reduced cell proliferation, increased apoptosis, and decreased anchorage-independent growth.
  • Xenograft tumor growth was not significantly affected by NRas or HRas disruption, unlike KRas disruption.
  • Deletion of mutant KRas abolished tumor growth, while deletion of WT KRas enhanced tumorigenicity.

Conclusions:

  • WT HRas, NRas, and KRas exhibit distinct functions within mutant KRas-driven tumors.
  • The cellular context of mutant KRas influences the roles of WT Ras isoforms.
  • Understanding these unique roles is crucial for developing targeted cancer therapies.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...